People | March 30, 2022
Sara Gutierrez joins SHL as the Chief Science Officer
The science leader comes with a rich experience in the employment testing industry
The science leader comes with a rich experience in the employment testing industry
World-leading companies, as well as small innovative research groups, regularly partner with Medanex for their outstanding cardiovascular services and timely, efficacious study outcomes.
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Novel tool bypasses plasmid-based expression to increase stability and significantly reduce development time for a variety of synthetic biotechnology products
The funding will accelerate the AI-driven healthcare company's market expansion into the global market and support new product development
Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults
Dupixent peak sales ambition raised to more than €13 billion
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
Subscribe To Our Newsletter & Stay Updated
